• Cristiane Almeida Soares CattaniEmail author
  • Renata Heck


Cutaneous manifestations of systemic diseases can be an early sign or a late presentation of chronic disease. All practitioners should be familiar with common dermatologic lesions of generalized medical conditions so that they may properly diagnose and treat the patient or refer the patient to the proper specialist. This chapter addresses dyslipidemias and their epidemiology, etiopathogenesis, classification, and characteristic skin manifestation, namely, xanthomas. Being familiar with the clinical features, histopathology, and differential diagnosis of xanthomas helps to provide an early diagnosis and follow-up of different forms of dyslipidemia. Dermatologists must be aware that removing xanthomas is of no help if the underlying cause is not approached diagnostically and therapeutically.


Xanthomas Hyperlipidemia Hypercholesterolemia Tuberous xanthomas Xanthelasma 


  1. 1.
    Pai VV, Shukla P, Bhobe M. Combined planar and eruptive xanthoma in a patient with type lla hyperlipoproteinemia. Indian J Dermatol Venereol Leprol. 2014;80(5):467–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Massengale WT, Hodari KT, Boh EE, Nesbitt LT. Xanthomas. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Philadelphia, Elsevier; 2012. p. 1547–55.Google Scholar
  3. 3.
    Gigante DP, Moura EC, Sardinha LM. Prevalence of overweight and obesity and associated factors, Brazil, 2006. Rev Saude Publica. 2009;43(2):83–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Bruckert E, Hansel B. Familial hypercholesterolemia (Part 1): diagnosis and screening challenges. In: Medscape [Internet]. Accessed 10 Apr 2016.Google Scholar
  5. 5.
    Paller AS, Mancini AJ. Inborn errors of metabolism. In: Hurwitz clinical pediatric dermatology. 4th ed. Philadelphia, Elsevier; 2011. p. 553–7.Google Scholar
  6. 6.
    Gao H, Chen J. Eruptive xanthomas presenting in tattoos. CMAJ. 2015;187(5):356.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schaefer EJ, Santos RD. Xanthomatoses and lipoprotein disorders. In: Goldsmith LA, Katz SI, Gilchrest BA, et al., editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York, McGraw-Hill Companies; 2012. p. 1600–12.Google Scholar
  8. 8.
    Sethuraman G, Thappa DM, Karthikeyan K. Intertriginous xanthomas – a marker of homozygous familial hypercholesterolemia. Indian Pediatr. 2000;37:338.Google Scholar
  9. 9.
    Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986;57:29H–35H.CrossRefPubMedGoogle Scholar
  10. 10.
    Bhagwat PV, Tophakhane RS, Kudligi C, Noronha TM, Thirunavukkarasu A. Familial combined hypercholesterolemia type IIb presenting with tuberous xanthoma, tendinous xanthoma and pityriasis rubra pilaris-like lesions. Indian J Dermatol Venereol Leprol. 2010;76(3):293–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Rohrs HJ, Berger S. Pediatric lipid disorders in clinical practice. In Medscape [Internet]. Accessed 10 Apr 2016.Google Scholar
  12. 12.
    Shenoy C, Shenoy MM, Rao GK. Dyslipidemia in dermatological disorders. N Am J Med Sci. 2015;7(10):421–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vieira JLC, Vieira PL, Moriguchi EH. Hipolipemiantes. In: Barros E, Barros H. Medicamentos na prática clínica. 1st ed. Porto Alegre, Artmed; 2010. p. 288–303.Google Scholar
  14. 14.
    Rosenson RS, Freeman MW, Rind DM. Statins: actions, side effects, and administration. In: UpToDate [Internet]. WoltersKluwer Health. The Netherlands. Accessed 27 Mar 2016.Google Scholar
  15. 15.
    Rosenson RS, Freeman MW, Rind DM. Lipid lowering with fibric acid derivatives. In: UpToDate [Internet]. WoltersKluwer Health. The Netherlands. Accessed 27 Mar 2016.Google Scholar
  16. 16.
    Rosenson RS, Freeman MW, Rind DM. Lipid lowering with drugs other than statins and fibrates. In: UpToDate [Internet]. WoltersKluwer Health. The Netherlands. Accessed 27 Mar 2016.Google Scholar
  17. 17.
    Sando KR, Knight M. Therapies for management of dyslipidemia: a review. Clin Ther. 2015;37(10):2153–79.CrossRefPubMedGoogle Scholar
  18. 18.
    White LE, Horenstein MG, Shea CR. Xanthomas. In Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. Treatment of skin disease. 4th ed. Elsevier; Philadelphia, 2014. p 804–807Google Scholar
  19. 19.
    Goel K, Sardana K, Garg VK. A prospective study comparing ultrapulse CO2 laser and trichloroacetic acid in treatment of Xanthelasma palpebrarum. J Cosmet Dermatol. 2015;14(2):130–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  • Cristiane Almeida Soares Cattani
    • 1
    Email author
  • Renata Heck
    • 1
  1. 1.Sanitary Dermatology Service of the Department of Health of Rio Grande do Sul StatePorto AlegreBrazil

Personalised recommendations